Chronic Liver Diseases Therapeutics Market Report 2026

Chronic Liver Diseases Therapeutics Market Overview

• Chronic Liver Diseases Therapeutics market size has reached to $15.88 billion in 2025 • Expected to grow to $25.99 billion in 2030 at a compound annual growth rate (CAGR) of 10.3% • Growth Driver: Market Growth Driven By Increased Alcohol Use And Liver Health Challenges • Market Trend: Advancements In Autologous Macrophage–Based Therapeutic Innovations • North America was the largest region in 2025.

What Is Covered Under Chronic Liver Diseases Therapeutics Market?

Chronic liver disease therapeutics refers to the medical treatments and interventions aimed at managing long-term liver conditions. These therapies focus on slowing disease progression, alleviating symptoms, and improving liver function through medications, lifestyle changes, and, in some cases, advanced procedures. The main treatment types of chronic liver diseases therapeutics are antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Antiviral drugs are medications designed to prevent the replication of viruses in the body, helping to treat and manage viral infections. These treatments address various disease types, including hepatitis, autoimmune diseases, non-alcoholic fatty liver disease, cancer, and genetic disorders. It is distributed through various applications such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Chronic Liver Diseases Therapeutics Market Growth Forecast?

The chronic liver diseases therapeutics market size is expected to see rapid growth in the next few years. It will grow to $25.99 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing investments in NASH and fibrosis therapies, rising demand for precision liver medicine, expansion of biologic and targeted treatments, growing focus on early intervention strategies, increased clinical trial activity in liver diseases. Major trends in the forecast period include increasing development of targeted liver therapies, rising focus on disease-specific treatment approaches, growing adoption of combination drug regimens, expansion of non-invasive disease monitoring, enhanced emphasis on slowing disease progression.

Global Chronic Liver Diseases Therapeutics Market Segmentation

1) By Treatment Type: Antiviral Drugs, Immunosuppressants Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy 2) By Disease Type: Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Cancer, Genetic Disorders 3) By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues, Interferons, Direct-Acting Antivirals 2) By Immunosuppressants Vaccines: Calcineurin Inhibitors, mTOR Inhibitors, Purine Synthesis Inhibitors 3) By Immunoglobulins: Hepatitis B Immune Globulin, Intravenous Immunoglobulin 4) By Corticosteroids: Prednisolone, Methylprednisolone, Dexamethasone 5) By Targeted Therapy: Tyrosine Kinase Inhibitors, Monoclonal Antibodies 6) By Chemotherapy: Systemic Chemotherapy, Transarterial Chemoembolization Agents

What Is The Driver Of The Chronic Liver Diseases Therapeutics Market?

Increasing alcohol consumption is expected to propel the growth of the chronic liver disease therapeutics market going forward. Alcohol consumption is the intake of beverages containing ethanol, ranging from moderate to excessive use, with potential health impacts. Increasing alcohol consumption is due to growing social acceptance, rising incomes, and greater accessibility worldwide. Chronic liver disease therapeutics help manage liver damage caused by excessive alcohol consumption, slowing disease progression and improving liver function. For instance, in June 2024, according to the First Citizens Bank, a US financial institution, there was a 1.2% increase in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022. Additionally, in December 2023, according to the report published by Kirin Holdings Company Limited, a Japan-based beverage company, it was noted that around 192.1 million kiloliters of beer were consumed in 2022, reflecting a 2.9% increase from the previous year. Therefore, the increasing alcohol consumption is driving the growth of the chronic liver disease therapeutics market.

Key Players In The Global Chronic Liver Diseases Therapeutics Market

Major companies operating in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy's Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

Global Chronic Liver Diseases Therapeutics Market Trends and Insights

Major companies operating in the chronic liver disease therapeutics market are focusing on developing innovative solutions such as engineered autologous macrophage cell therapy to enhance liver regeneration, reduce fibrosis progression, and provide more targeted, disease-modifying treatment options. Engineered autologous macrophage cell therapy refers to a treatment approach that uses a patient’s own macrophages, which are genetically modified or functionally enhanced outside the body, and then reinfused to reduce liver inflammation, promote tissue repair, and slow or reverse fibrosis in chronic liver diseases. For instance, in June 2024, Resolution Therapeutics Ltd., a UK-based biotechnology company, received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to commence its Phase I/II EMERALD study for the lead candidate RTX001, targeting decompensated liver cirrhosis.

What Are Latest Mergers And Acquisitions In The Chronic Liver Diseases Therapeutics Market?

In March 2024, Gilead Sciences Inc., a US-based pharmaceutical company, acquired CymaBay Therapeutics Inc. for approximately $4.3 billion. With this acquisition, Gilead Sciences aims to expand its portfolio in liver diseases, particularly focusing on non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. CymaBay Therapeutics Inc. is a US-based company that focuses on developing therapies for liver diseases, including chronic liver conditions.

Regional Outlook

North America was the largest region in the chronic liver diseases therapeutics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chronic Liver Diseases Therapeutics Market?

The chronic liver disease therapeutics market includes revenues earned by entities by providing services such as genetic and molecular testing, liver transplantation, enzyme inhibitors, regular monitoring, and palliative and symptomatic care and related products, including pharmacological treatments, drugs, and emerging therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Liver Diseases Therapeutics Market Report 2026?

The chronic liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic liver diseases therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.